DE60225141T2 - Verfahren zur erhöhung der in vivo wirksamkeit von oligonukleotiden und zur entzündungshemmung in säugetieren - Google Patents
Verfahren zur erhöhung der in vivo wirksamkeit von oligonukleotiden und zur entzündungshemmung in säugetieren Download PDFInfo
- Publication number
- DE60225141T2 DE60225141T2 DE60225141T DE60225141T DE60225141T2 DE 60225141 T2 DE60225141 T2 DE 60225141T2 DE 60225141 T DE60225141 T DE 60225141T DE 60225141 T DE60225141 T DE 60225141T DE 60225141 T2 DE60225141 T2 DE 60225141T2
- Authority
- DE
- Germany
- Prior art keywords
- nucleic acid
- acid molecule
- diseases
- dap
- group
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Lifetime
Links
- 108091034117 Oligonucleotide Proteins 0.000 title claims abstract description 85
- 238000000034 method Methods 0.000 title claims description 25
- 241000124008 Mammalia Species 0.000 title abstract description 11
- JLCPHMBAVCMARE-UHFFFAOYSA-N [3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-hydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methyl [5-(6-aminopurin-9-yl)-2-(hydroxymethyl)oxolan-3-yl] hydrogen phosphate Polymers Cc1cn(C2CC(OP(O)(=O)OCC3OC(CC3OP(O)(=O)OCC3OC(CC3O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c3nc(N)[nH]c4=O)C(COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3CO)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cc(C)c(=O)[nH]c3=O)n3cc(C)c(=O)[nH]c3=O)n3ccc(N)nc3=O)n3cc(C)c(=O)[nH]c3=O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)O2)c(=O)[nH]c1=O JLCPHMBAVCMARE-UHFFFAOYSA-N 0.000 title description 32
- 230000002757 inflammatory effect Effects 0.000 title description 4
- 230000005764 inhibitory process Effects 0.000 title description 4
- 150000007523 nucleic acids Chemical class 0.000 claims abstract description 118
- 108020004707 nucleic acids Proteins 0.000 claims abstract description 115
- 102000039446 nucleic acids Human genes 0.000 claims abstract description 115
- 239000000074 antisense oligonucleotide Substances 0.000 claims abstract description 72
- 238000012230 antisense oligonucleotides Methods 0.000 claims abstract description 72
- 239000002773 nucleotide Substances 0.000 claims abstract description 39
- 239000000203 mixture Substances 0.000 claims abstract description 32
- 238000001727 in vivo Methods 0.000 claims abstract description 26
- 230000004054 inflammatory process Effects 0.000 claims abstract description 18
- 206010061218 Inflammation Diseases 0.000 claims abstract description 16
- 208000006673 asthma Diseases 0.000 claims abstract description 16
- 230000003110 anti-inflammatory effect Effects 0.000 claims abstract description 14
- 125000003729 nucleotide group Chemical group 0.000 claims abstract description 14
- 201000003883 Cystic fibrosis Diseases 0.000 claims abstract description 10
- 206010020751 Hypersensitivity Diseases 0.000 claims abstract description 9
- 206010028980 Neoplasm Diseases 0.000 claims abstract description 9
- 201000011510 cancer Diseases 0.000 claims abstract description 9
- 208000005069 pulmonary fibrosis Diseases 0.000 claims abstract description 9
- 208000023504 respiratory system disease Diseases 0.000 claims abstract description 9
- 206010001052 Acute respiratory distress syndrome Diseases 0.000 claims abstract description 8
- 208000006545 Chronic Obstructive Pulmonary Disease Diseases 0.000 claims abstract description 8
- 206010039085 Rhinitis allergic Diseases 0.000 claims abstract description 8
- 201000010105 allergic rhinitis Diseases 0.000 claims abstract description 8
- 230000007815 allergy Effects 0.000 claims abstract description 8
- 206010006458 Bronchitis chronic Diseases 0.000 claims abstract description 7
- 206010006451 bronchitis Diseases 0.000 claims abstract description 7
- 208000007451 chronic bronchitis Diseases 0.000 claims abstract description 7
- 206010065563 Eosinophilic bronchitis Diseases 0.000 claims abstract description 6
- 238000002360 preparation method Methods 0.000 claims abstract description 5
- 208000013616 Respiratory Distress Syndrome Diseases 0.000 claims abstract description 4
- 208000011341 adult acute respiratory distress syndrome Diseases 0.000 claims abstract description 4
- 201000000028 adult respiratory distress syndrome Diseases 0.000 claims abstract description 4
- OIRDTQYFTABQOQ-KQYNXXCUSA-N adenosine Chemical compound C1=NC=2C(N)=NC=NC=2N1[C@@H]1O[C@H](CO)[C@@H](O)[C@H]1O OIRDTQYFTABQOQ-KQYNXXCUSA-N 0.000 claims description 219
- 239000002126 C01EB10 - Adenosine Substances 0.000 claims description 97
- 229960005305 adenosine Drugs 0.000 claims description 97
- 230000000692 anti-sense effect Effects 0.000 claims description 58
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 45
- 201000010099 disease Diseases 0.000 claims description 44
- 210000004072 lung Anatomy 0.000 claims description 44
- 210000002345 respiratory system Anatomy 0.000 claims description 31
- 108090000623 proteins and genes Proteins 0.000 claims description 25
- 239000003814 drug Substances 0.000 claims description 18
- MSSXOMSJDRHRMC-UHFFFAOYSA-N 9H-purine-2,6-diamine Chemical compound NC1=NC(N)=C2NC=NC2=N1 MSSXOMSJDRHRMC-UHFFFAOYSA-N 0.000 claims description 17
- 238000011282 treatment Methods 0.000 claims description 17
- -1 phosphotriester Chemical compound 0.000 claims description 16
- RYYWUUFWQRZTIU-UHFFFAOYSA-K thiophosphate Chemical compound [O-]P([O-])([O-])=S RYYWUUFWQRZTIU-UHFFFAOYSA-K 0.000 claims description 16
- 108020004414 DNA Proteins 0.000 claims description 15
- 230000001225 therapeutic effect Effects 0.000 claims description 15
- RYYWUUFWQRZTIU-UHFFFAOYSA-N Thiophosphoric acid Chemical group OP(O)(S)=O RYYWUUFWQRZTIU-UHFFFAOYSA-N 0.000 claims description 12
- 230000002265 prevention Effects 0.000 claims description 12
- 150000003839 salts Chemical class 0.000 claims description 12
- 208000026350 Inborn Genetic disease Diseases 0.000 claims description 11
- 208000016361 genetic disease Diseases 0.000 claims description 11
- 208000015181 infectious disease Diseases 0.000 claims description 11
- 230000001717 pathogenic effect Effects 0.000 claims description 10
- 239000000126 substance Substances 0.000 claims description 9
- 206010014950 Eosinophilia Diseases 0.000 claims description 8
- 208000026935 allergic disease Diseases 0.000 claims description 8
- 238000002560 therapeutic procedure Methods 0.000 claims description 8
- 201000009030 Carcinoma Diseases 0.000 claims description 7
- 108091028043 Nucleic acid sequence Proteins 0.000 claims description 7
- 150000002632 lipids Chemical class 0.000 claims description 7
- 239000000463 material Substances 0.000 claims description 7
- 208000017520 skin disease Diseases 0.000 claims description 7
- 208000024172 Cardiovascular disease Diseases 0.000 claims description 6
- 208000012902 Nervous system disease Diseases 0.000 claims description 6
- 208000025966 Neurological disease Diseases 0.000 claims description 6
- 208000025747 Rheumatic disease Diseases 0.000 claims description 6
- 150000003838 adenosines Chemical class 0.000 claims description 6
- 208000010643 digestive system disease Diseases 0.000 claims description 6
- 210000000056 organ Anatomy 0.000 claims description 6
- 239000003937 drug carrier Substances 0.000 claims description 5
- 238000004519 manufacturing process Methods 0.000 claims description 5
- 102000004169 proteins and genes Human genes 0.000 claims description 5
- 230000002485 urinary effect Effects 0.000 claims description 5
- 206010049153 Allergic sinusitis Diseases 0.000 claims description 4
- UCKMPCXJQFINFW-UHFFFAOYSA-N Sulphide Chemical compound [S-2] UCKMPCXJQFINFW-UHFFFAOYSA-N 0.000 claims description 4
- 229940079593 drug Drugs 0.000 claims description 4
- 239000008194 pharmaceutical composition Substances 0.000 claims description 4
- 150000001413 amino acids Chemical class 0.000 claims description 3
- 239000000872 buffer Substances 0.000 claims description 3
- 239000003795 chemical substances by application Substances 0.000 claims description 3
- 239000002270 dispersing agent Substances 0.000 claims description 3
- 239000003446 ligand Substances 0.000 claims description 3
- 239000000816 peptidomimetic Substances 0.000 claims description 3
- 102000004196 processed proteins & peptides Human genes 0.000 claims description 3
- 108090000765 processed proteins & peptides Proteins 0.000 claims description 3
- 239000000080 wetting agent Substances 0.000 claims description 3
- KXDHJXZQYSOELW-UHFFFAOYSA-M Carbamate Chemical compound NC([O-])=O KXDHJXZQYSOELW-UHFFFAOYSA-M 0.000 claims description 2
- BVKZGUZCCUSVTD-UHFFFAOYSA-L Carbonate Chemical compound [O-]C([O-])=O BVKZGUZCCUSVTD-UHFFFAOYSA-L 0.000 claims description 2
- AVXURJPOCDRRFD-UHFFFAOYSA-N Hydroxylamine Chemical compound ON AVXURJPOCDRRFD-UHFFFAOYSA-N 0.000 claims description 2
- QAOWNCQODCNURD-UHFFFAOYSA-L Sulfate Chemical compound [O-]S([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-L 0.000 claims description 2
- 239000003963 antioxidant agent Substances 0.000 claims description 2
- JXLHNMVSKXFWAO-UHFFFAOYSA-N azane;7-fluoro-2,1,3-benzoxadiazole-4-sulfonic acid Chemical compound N.OS(=O)(=O)C1=CC=C(F)C2=NON=C12 JXLHNMVSKXFWAO-UHFFFAOYSA-N 0.000 claims description 2
- 239000002775 capsule Substances 0.000 claims description 2
- NAGJZTKCGNOGPW-UHFFFAOYSA-K dioxido-sulfanylidene-sulfido-$l^{5}-phosphane Chemical compound [O-]P([O-])([S-])=S NAGJZTKCGNOGPW-UHFFFAOYSA-K 0.000 claims description 2
- 229940112141 dry powder inhaler Drugs 0.000 claims description 2
- 239000007788 liquid Substances 0.000 claims description 2
- 125000000325 methylidene group Chemical group [H]C([H])=* 0.000 claims description 2
- YACKEPLHDIMKIO-UHFFFAOYSA-N methylphosphonic acid Chemical compound CP(O)(O)=O YACKEPLHDIMKIO-UHFFFAOYSA-N 0.000 claims description 2
- 239000013081 microcrystal Substances 0.000 claims description 2
- 239000006199 nebulizer Substances 0.000 claims description 2
- 239000002245 particle Substances 0.000 claims description 2
- PTMHPRAIXMAOOB-UHFFFAOYSA-N phosphoramidic acid Chemical group NP(O)(O)=O PTMHPRAIXMAOOB-UHFFFAOYSA-N 0.000 claims description 2
- 239000003755 preservative agent Substances 0.000 claims description 2
- 239000007787 solid Substances 0.000 claims description 2
- IIACRCGMVDHOTQ-UHFFFAOYSA-M sulfamate Chemical compound NS([O-])(=O)=O IIACRCGMVDHOTQ-UHFFFAOYSA-M 0.000 claims description 2
- 229940124530 sulfonamide Drugs 0.000 claims description 2
- 150000003456 sulfonamides Chemical class 0.000 claims description 2
- 150000003457 sulfones Chemical class 0.000 claims description 2
- 150000003462 sulfoxides Chemical class 0.000 claims description 2
- 229910021653 sulphate ion Inorganic materials 0.000 claims description 2
- 150000003568 thioethers Chemical class 0.000 claims description 2
- 239000000341 volatile oil Substances 0.000 claims description 2
- 125000000837 carbohydrate group Chemical group 0.000 claims 2
- 239000004604 Blowing Agent Substances 0.000 claims 1
- 239000000443 aerosol Substances 0.000 claims 1
- YZYDPPZYDIRSJT-UHFFFAOYSA-K boron phosphate Chemical compound [B+3].[O-]P([O-])([O-])=O YZYDPPZYDIRSJT-UHFFFAOYSA-K 0.000 claims 1
- 229910000149 boron phosphate Inorganic materials 0.000 claims 1
- 239000003153 chemical reaction reagent Substances 0.000 claims 1
- 125000005647 linker group Chemical group 0.000 claims 1
- 229940071648 metered dose inhaler Drugs 0.000 claims 1
- 239000007922 nasal spray Substances 0.000 claims 1
- 229940097496 nasal spray Drugs 0.000 claims 1
- 150000004713 phosphodiesters Chemical class 0.000 claims 1
- 108020000948 Antisense Oligonucleotides Proteins 0.000 abstract description 49
- 231100000419 toxicity Toxicity 0.000 abstract description 23
- 230000001988 toxicity Effects 0.000 abstract description 23
- 230000002401 inhibitory effect Effects 0.000 abstract description 12
- 230000002685 pulmonary effect Effects 0.000 abstract description 9
- 230000002829 reductive effect Effects 0.000 abstract description 9
- 241000725643 Respiratory syncytial virus Species 0.000 abstract description 5
- VKKXEIQIGGPMHT-UHFFFAOYSA-N 7h-purine-2,8-diamine Chemical compound NC1=NC=C2NC(N)=NC2=N1 VKKXEIQIGGPMHT-UHFFFAOYSA-N 0.000 abstract description 3
- 201000009890 sinusitis Diseases 0.000 abstract description 3
- 208000019693 Lung disease Diseases 0.000 abstract description 2
- 206010062106 Respiratory tract infection viral Diseases 0.000 abstract description 2
- 208000020017 viral respiratory tract infection Diseases 0.000 abstract 1
- 210000004027 cell Anatomy 0.000 description 36
- 241000700159 Rattus Species 0.000 description 35
- 230000000694 effects Effects 0.000 description 23
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 17
- NOLHIMIFXOBLFF-KVQBGUIXSA-N (2r,3s,5r)-5-(2,6-diaminopurin-9-yl)-2-(hydroxymethyl)oxolan-3-ol Chemical compound C12=NC(N)=NC(N)=C2N=CN1[C@H]1C[C@H](O)[C@@H](CO)O1 NOLHIMIFXOBLFF-KVQBGUIXSA-N 0.000 description 16
- 102000000646 Interleukin-3 Human genes 0.000 description 16
- 101500011073 Diploptera punctata Allatostatin-5 Proteins 0.000 description 15
- UGQMRVRMYYASKQ-KQYNXXCUSA-N Inosine Chemical compound O[C@@H]1[C@H](O)[C@@H](CO)O[C@H]1N1C2=NC=NC(O)=C2N=C1 UGQMRVRMYYASKQ-KQYNXXCUSA-N 0.000 description 15
- 108010058846 Ovalbumin Proteins 0.000 description 14
- 229960003786 inosine Drugs 0.000 description 14
- 229940092253 ovalbumin Drugs 0.000 description 14
- 229930010555 Inosine Natural products 0.000 description 13
- 239000000427 antigen Substances 0.000 description 12
- 102000036639 antigens Human genes 0.000 description 12
- 108091007433 antigens Proteins 0.000 description 12
- 210000003979 eosinophil Anatomy 0.000 description 12
- 238000002347 injection Methods 0.000 description 12
- 239000007924 injection Substances 0.000 description 12
- 108010038484 Interleukin-5 Receptors Proteins 0.000 description 11
- 239000011780 sodium chloride Substances 0.000 description 11
- NOLHIMIFXOBLFF-UHFFFAOYSA-N 2-Amino-2'-deoxyadenosine Natural products C12=NC(N)=NC(N)=C2N=CN1C1CC(O)C(CO)O1 NOLHIMIFXOBLFF-UHFFFAOYSA-N 0.000 description 9
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 9
- 108010002386 Interleukin-3 Proteins 0.000 description 9
- IUJDSEJGGMCXSG-UHFFFAOYSA-N Thiopental Chemical compound CCCC(C)C1(CC)C(=O)NC(=S)NC1=O IUJDSEJGGMCXSG-UHFFFAOYSA-N 0.000 description 9
- 238000002695 general anesthesia Methods 0.000 description 9
- 230000004941 influx Effects 0.000 description 9
- 210000004698 lymphocyte Anatomy 0.000 description 9
- 210000002540 macrophage Anatomy 0.000 description 9
- 108700025647 major vault Proteins 0.000 description 9
- 229940043200 pentothal Drugs 0.000 description 9
- 108091032973 (ribonucleotides)n+m Proteins 0.000 description 8
- 238000011835 investigation Methods 0.000 description 8
- 101150112014 Gapdh gene Proteins 0.000 description 7
- 102000016355 Granulocyte-Macrophage Colony-Stimulating Factor Receptors Human genes 0.000 description 7
- 108010092372 Granulocyte-Macrophage Colony-Stimulating Factor Receptors Proteins 0.000 description 7
- 108010038452 Interleukin-3 Receptors Proteins 0.000 description 7
- 102000000743 Interleukin-5 Human genes 0.000 description 7
- 230000004071 biological effect Effects 0.000 description 7
- 150000001875 compounds Chemical class 0.000 description 7
- 108010017213 Granulocyte-Macrophage Colony-Stimulating Factor Proteins 0.000 description 6
- 102000004457 Granulocyte-Macrophage Colony-Stimulating Factor Human genes 0.000 description 6
- 241001465754 Metazoa Species 0.000 description 6
- 206010070834 Sensitisation Diseases 0.000 description 6
- 238000011685 brown norway rat Methods 0.000 description 6
- 238000001415 gene therapy Methods 0.000 description 6
- 238000000338 in vitro Methods 0.000 description 6
- 210000000440 neutrophil Anatomy 0.000 description 6
- 230000000770 proinflammatory effect Effects 0.000 description 6
- 230000000241 respiratory effect Effects 0.000 description 6
- 230000008313 sensitization Effects 0.000 description 6
- 101000746373 Homo sapiens Granulocyte-macrophage colony-stimulating factor Proteins 0.000 description 5
- 102000010786 Interleukin-5 Receptors Human genes 0.000 description 5
- 238000005516 engineering process Methods 0.000 description 5
- 102000046157 human CSF2 Human genes 0.000 description 5
- 102000005962 receptors Human genes 0.000 description 5
- 108020003175 receptors Proteins 0.000 description 5
- 230000004043 responsiveness Effects 0.000 description 5
- 229960005486 vaccine Drugs 0.000 description 5
- ZDTFMPXQUSBYRL-UUOKFMHZSA-N 2-Aminoadenosine Chemical compound C12=NC(N)=NC(N)=C2N=CN1[C@@H]1O[C@H](CO)[C@@H](O)[C@H]1O ZDTFMPXQUSBYRL-UUOKFMHZSA-N 0.000 description 4
- 102000004499 CCR3 Receptors Human genes 0.000 description 4
- DYSDOYRQWBDGQQ-XLPZGREQSA-N N6-Methyl-2'-deoxyadenosine Chemical compound C1=NC=2C(NC)=NC=NC=2N1[C@H]1C[C@H](O)[C@@H](CO)O1 DYSDOYRQWBDGQQ-XLPZGREQSA-N 0.000 description 4
- 101000980728 Rattus norvegicus C-C chemokine receptor type 3 Proteins 0.000 description 4
- 239000005557 antagonist Substances 0.000 description 4
- 230000001413 cellular effect Effects 0.000 description 4
- 230000003247 decreasing effect Effects 0.000 description 4
- 230000014509 gene expression Effects 0.000 description 4
- 239000002777 nucleoside Substances 0.000 description 4
- 230000009885 systemic effect Effects 0.000 description 4
- 102000009346 Adenosine receptors Human genes 0.000 description 3
- 108050000203 Adenosine receptors Proteins 0.000 description 3
- 206010006482 Bronchospasm Diseases 0.000 description 3
- 206010011224 Cough Diseases 0.000 description 3
- DYSDOYRQWBDGQQ-UHFFFAOYSA-N N6-Methyldeoxyadenosine Natural products C1=NC=2C(NC)=NC=NC=2N1C1CC(O)C(CO)O1 DYSDOYRQWBDGQQ-UHFFFAOYSA-N 0.000 description 3
- 206010035664 Pneumonia Diseases 0.000 description 3
- 101000746366 Rattus norvegicus Granulocyte-macrophage colony-stimulating factor Proteins 0.000 description 3
- 238000013459 approach Methods 0.000 description 3
- 230000027455 binding Effects 0.000 description 3
- 239000000969 carrier Substances 0.000 description 3
- 238000011161 development Methods 0.000 description 3
- 239000012634 fragment Substances 0.000 description 3
- 229910052739 hydrogen Inorganic materials 0.000 description 3
- 239000001257 hydrogen Substances 0.000 description 3
- 238000010348 incorporation Methods 0.000 description 3
- 238000001802 infusion Methods 0.000 description 3
- YEESKJGWJFYOOK-IJHYULJSSA-N leukotriene D4 Chemical compound CCCCC\C=C/C\C=C/C=C/C=C/[C@H]([C@@H](O)CCCC(O)=O)SC[C@H](N)C(=O)NCC(O)=O YEESKJGWJFYOOK-IJHYULJSSA-N 0.000 description 3
- 231100000053 low toxicity Toxicity 0.000 description 3
- 230000007246 mechanism Effects 0.000 description 3
- 239000002609 medium Substances 0.000 description 3
- 108020004999 messenger RNA Proteins 0.000 description 3
- 238000012986 modification Methods 0.000 description 3
- 230000004048 modification Effects 0.000 description 3
- 244000052769 pathogen Species 0.000 description 3
- 238000003752 polymerase chain reaction Methods 0.000 description 3
- 125000001424 substituent group Chemical group 0.000 description 3
- 239000000725 suspension Substances 0.000 description 3
- 238000002627 tracheal intubation Methods 0.000 description 3
- CQKMBZHLOYVGHW-QYYRPYCUSA-N (2r,3s,4r,5r)-4-amino-5-(6-aminopurin-9-yl)-2-(hydroxymethyl)oxolan-3-ol Chemical compound N[C@@H]1[C@H](O)[C@@H](CO)O[C@H]1N1C2=NC=NC(N)=C2N=C1 CQKMBZHLOYVGHW-QYYRPYCUSA-N 0.000 description 2
- NIJSNUNKSPLDTO-DJLDLDEBSA-N 2'-deoxytubercidin Chemical compound C1=CC=2C(N)=NC=NC=2N1[C@H]1C[C@H](O)[C@@H](CO)O1 NIJSNUNKSPLDTO-DJLDLDEBSA-N 0.000 description 2
- KDCGOANMDULRCW-UHFFFAOYSA-N 7H-purine Chemical compound N1=CNC2=NC=NC2=C1 KDCGOANMDULRCW-UHFFFAOYSA-N 0.000 description 2
- 229930024421 Adenine Natural products 0.000 description 2
- GFFGJBXGBJISGV-UHFFFAOYSA-N Adenine Chemical compound NC1=NC=NC2=C1N=CN2 GFFGJBXGBJISGV-UHFFFAOYSA-N 0.000 description 2
- 108010088751 Albumins Proteins 0.000 description 2
- 102000009027 Albumins Human genes 0.000 description 2
- 101710149862 C-C chemokine receptor type 3 Proteins 0.000 description 2
- 102100024167 C-C chemokine receptor type 3 Human genes 0.000 description 2
- 108010017316 CCR3 Receptors Proteins 0.000 description 2
- 108020004635 Complementary DNA Proteins 0.000 description 2
- 241000021525 Cyanophage S-2L Species 0.000 description 2
- NYHBQMYGNKIUIF-UUOKFMHZSA-N Guanosine Chemical compound C1=NC=2C(=O)NC(N)=NC=2N1[C@@H]1O[C@H](CO)[C@@H](O)[C@H]1O NYHBQMYGNKIUIF-UUOKFMHZSA-N 0.000 description 2
- 241000725303 Human immunodeficiency virus Species 0.000 description 2
- 206010058467 Lung neoplasm malignant Diseases 0.000 description 2
- 241000699670 Mus sp. Species 0.000 description 2
- 239000013543 active substance Substances 0.000 description 2
- 229960000643 adenine Drugs 0.000 description 2
- 208000037883 airway inflammation Diseases 0.000 description 2
- 238000003556 assay Methods 0.000 description 2
- 230000008901 benefit Effects 0.000 description 2
- 230000015572 biosynthetic process Effects 0.000 description 2
- 230000000903 blocking effect Effects 0.000 description 2
- UORVGPXVDQYIDP-UHFFFAOYSA-N borane Chemical compound B UORVGPXVDQYIDP-UHFFFAOYSA-N 0.000 description 2
- 230000007885 bronchoconstriction Effects 0.000 description 2
- 230000015556 catabolic process Effects 0.000 description 2
- 230000001684 chronic effect Effects 0.000 description 2
- OPTASPLRGRRNAP-UHFFFAOYSA-N cytosine Chemical compound NC=1C=CNC(=O)N=1 OPTASPLRGRRNAP-UHFFFAOYSA-N 0.000 description 2
- 238000006731 degradation reaction Methods 0.000 description 2
- 230000003292 diminished effect Effects 0.000 description 2
- 238000009826 distribution Methods 0.000 description 2
- 230000002327 eosinophilic effect Effects 0.000 description 2
- 230000006870 function Effects 0.000 description 2
- 230000002489 hematologic effect Effects 0.000 description 2
- 238000009396 hybridization Methods 0.000 description 2
- 230000035874 hyperreactivity Effects 0.000 description 2
- 208000027866 inflammatory disease Diseases 0.000 description 2
- 230000028709 inflammatory response Effects 0.000 description 2
- 231100001231 less toxic Toxicity 0.000 description 2
- 238000005259 measurement Methods 0.000 description 2
- 210000005170 neoplastic cell Anatomy 0.000 description 2
- 230000000414 obstructive effect Effects 0.000 description 2
- 230000007170 pathology Effects 0.000 description 2
- 230000003389 potentiating effect Effects 0.000 description 2
- 238000011552 rat model Methods 0.000 description 2
- 238000003753 real-time PCR Methods 0.000 description 2
- 230000010076 replication Effects 0.000 description 2
- 238000011160 research Methods 0.000 description 2
- 230000004044 response Effects 0.000 description 2
- 239000000243 solution Substances 0.000 description 2
- UCSJYZPVAKXKNQ-HZYVHMACSA-N streptomycin Chemical compound CN[C@H]1[C@H](O)[C@@H](O)[C@H](CO)O[C@H]1O[C@@H]1[C@](C=O)(O)[C@H](C)O[C@H]1O[C@@H]1[C@@H](NC(N)=N)[C@H](O)[C@@H](NC(N)=N)[C@H](O)[C@H]1O UCSJYZPVAKXKNQ-HZYVHMACSA-N 0.000 description 2
- 235000000346 sugar Nutrition 0.000 description 2
- 230000004083 survival effect Effects 0.000 description 2
- 238000003786 synthesis reaction Methods 0.000 description 2
- 229940124597 therapeutic agent Drugs 0.000 description 2
- 235000011178 triphosphate Nutrition 0.000 description 2
- 239000001226 triphosphate Substances 0.000 description 2
- UNXRWKVEANCORM-UHFFFAOYSA-N triphosphoric acid Chemical compound OP(O)(=O)OP(O)(=O)OP(O)(O)=O UNXRWKVEANCORM-UHFFFAOYSA-N 0.000 description 2
- GOJUJUVQIVIZAV-UHFFFAOYSA-N 2-amino-4,6-dichloropyrimidine-5-carbaldehyde Chemical group NC1=NC(Cl)=C(C=O)C(Cl)=N1 GOJUJUVQIVIZAV-UHFFFAOYSA-N 0.000 description 1
- CZMRCDWAGMRECN-UHFFFAOYSA-N 2-{[3,4-dihydroxy-2,5-bis(hydroxymethyl)oxolan-2-yl]oxy}-6-(hydroxymethyl)oxane-3,4,5-triol Chemical compound OCC1OC(CO)(OC2OC(CO)C(O)C(O)C2O)C(O)C1O CZMRCDWAGMRECN-UHFFFAOYSA-N 0.000 description 1
- HNHVJLBUCSUIFH-UHFFFAOYSA-N 7h-purine-2,6-diamine;sulfuric acid Chemical compound OS(O)(=O)=O.NC1=NC(N)=C2NC=NC2=N1.NC1=NC(N)=C2NC=NC2=N1 HNHVJLBUCSUIFH-UHFFFAOYSA-N 0.000 description 1
- 241001136792 Alle Species 0.000 description 1
- 206010002091 Anaesthesia Diseases 0.000 description 1
- 206010003645 Atopy Diseases 0.000 description 1
- 241000894006 Bacteria Species 0.000 description 1
- 208000031872 Body Remains Diseases 0.000 description 1
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 1
- 208000009079 Bronchial Spasm Diseases 0.000 description 1
- 208000014181 Bronchial disease Diseases 0.000 description 1
- 206010006448 Bronchiolitis Diseases 0.000 description 1
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 1
- 206010009137 Chronic sinusitis Diseases 0.000 description 1
- 108091026890 Coding region Proteins 0.000 description 1
- 206010010741 Conjunctivitis Diseases 0.000 description 1
- MIKUYHXYGGJMLM-GIMIYPNGSA-N Crotonoside Natural products C1=NC2=C(N)NC(=O)N=C2N1[C@H]1O[C@@H](CO)[C@H](O)[C@@H]1O MIKUYHXYGGJMLM-GIMIYPNGSA-N 0.000 description 1
- NYHBQMYGNKIUIF-UHFFFAOYSA-N D-guanosine Natural products C1=2NC(N)=NC(=O)C=2N=CN1C1OC(CO)C(O)C1O NYHBQMYGNKIUIF-UHFFFAOYSA-N 0.000 description 1
- 102000053602 DNA Human genes 0.000 description 1
- 238000011238 DNA vaccination Methods 0.000 description 1
- 238000007900 DNA-DNA hybridization Methods 0.000 description 1
- 241000709661 Enterovirus Species 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- JOYRKODLDBILNP-UHFFFAOYSA-N Ethyl urethane Chemical compound CCOC(N)=O JOYRKODLDBILNP-UHFFFAOYSA-N 0.000 description 1
- 108010002616 Interleukin-5 Proteins 0.000 description 1
- 102000004889 Interleukin-6 Human genes 0.000 description 1
- 108090001005 Interleukin-6 Proteins 0.000 description 1
- 102000010781 Interleukin-6 Receptors Human genes 0.000 description 1
- 108010038501 Interleukin-6 Receptors Proteins 0.000 description 1
- 102000018697 Membrane Proteins Human genes 0.000 description 1
- 108010052285 Membrane Proteins Proteins 0.000 description 1
- VVQNEPGJFQJSBK-UHFFFAOYSA-N Methyl methacrylate Chemical compound COC(=O)C(C)=C VVQNEPGJFQJSBK-UHFFFAOYSA-N 0.000 description 1
- 108091092724 Noncoding DNA Proteins 0.000 description 1
- 208000022873 Ocular disease Diseases 0.000 description 1
- 229910019142 PO4 Inorganic materials 0.000 description 1
- 229930182555 Penicillin Natural products 0.000 description 1
- JGSARLDLIJGVTE-MBNYWOFBSA-N Penicillin G Chemical compound N([C@H]1[C@H]2SC([C@@H](N2C1=O)C(O)=O)(C)C)C(=O)CC1=CC=CC=C1 JGSARLDLIJGVTE-MBNYWOFBSA-N 0.000 description 1
- 229920005372 Plexiglas® Polymers 0.000 description 1
- 239000004698 Polyethylene Substances 0.000 description 1
- 206010061924 Pulmonary toxicity Diseases 0.000 description 1
- 108091030071 RNAI Proteins 0.000 description 1
- 239000012980 RPMI-1640 medium Substances 0.000 description 1
- 208000002200 Respiratory Hypersensitivity Diseases 0.000 description 1
- 206010057190 Respiratory tract infections Diseases 0.000 description 1
- OUUQCZGPVNCOIJ-UHFFFAOYSA-M Superoxide Chemical compound [O-][O] OUUQCZGPVNCOIJ-UHFFFAOYSA-M 0.000 description 1
- 241000700605 Viruses Species 0.000 description 1
- 108091027569 Z-DNA Proteins 0.000 description 1
- OABUIHOVHQHUAO-NTSWFWBYSA-N [(2s,5r)-5-(2,6-diaminopurin-9-yl)oxolan-2-yl]methanol Chemical compound C12=NC(N)=NC(N)=C2N=CN1[C@H]1CC[C@@H](CO)O1 OABUIHOVHQHUAO-NTSWFWBYSA-N 0.000 description 1
- 230000004913 activation Effects 0.000 description 1
- 230000006978 adaptation Effects 0.000 description 1
- 239000004479 aerosol dispenser Substances 0.000 description 1
- 230000010085 airway hyperresponsiveness Effects 0.000 description 1
- 229940024546 aluminum hydroxide gel Drugs 0.000 description 1
- SMYKVLBUSSNXMV-UHFFFAOYSA-K aluminum;trihydroxide;hydrate Chemical compound O.[OH-].[OH-].[OH-].[Al+3] SMYKVLBUSSNXMV-UHFFFAOYSA-K 0.000 description 1
- 230000037005 anaesthesia Effects 0.000 description 1
- 230000000259 anti-tumor effect Effects 0.000 description 1
- 230000000840 anti-viral effect Effects 0.000 description 1
- 230000008827 biological function Effects 0.000 description 1
- 230000036760 body temperature Effects 0.000 description 1
- 229910000085 borane Inorganic materials 0.000 description 1
- 238000010804 cDNA synthesis Methods 0.000 description 1
- 150000001720 carbohydrates Chemical group 0.000 description 1
- 229910052799 carbon Inorganic materials 0.000 description 1
- 230000004663 cell proliferation Effects 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 210000000991 chicken egg Anatomy 0.000 description 1
- 208000013116 chronic cough Diseases 0.000 description 1
- 208000027157 chronic rhinosinusitis Diseases 0.000 description 1
- 238000003776 cleavage reaction Methods 0.000 description 1
- 238000004891 communication Methods 0.000 description 1
- 239000002299 complementary DNA Substances 0.000 description 1
- 239000006071 cream Substances 0.000 description 1
- 229940104302 cytosine Drugs 0.000 description 1
- 230000001419 dependent effect Effects 0.000 description 1
- 238000000586 desensitisation Methods 0.000 description 1
- 239000003085 diluting agent Substances 0.000 description 1
- 239000012895 dilution Substances 0.000 description 1
- 238000010790 dilution Methods 0.000 description 1
- LOKCTEFSRHRXRJ-UHFFFAOYSA-I dipotassium trisodium dihydrogen phosphate hydrogen phosphate dichloride Chemical compound P(=O)(O)(O)[O-].[K+].P(=O)(O)([O-])[O-].[Na+].[Na+].[Cl-].[K+].[Cl-].[Na+] LOKCTEFSRHRXRJ-UHFFFAOYSA-I 0.000 description 1
- 208000035475 disorder Diseases 0.000 description 1
- 238000009509 drug development Methods 0.000 description 1
- 230000000212 effect on lymphocytes Effects 0.000 description 1
- 238000006911 enzymatic reaction Methods 0.000 description 1
- 239000012894 fetal calf serum Substances 0.000 description 1
- 239000012847 fine chemical Substances 0.000 description 1
- 239000007789 gas Substances 0.000 description 1
- 230000009368 gene silencing by RNA Effects 0.000 description 1
- 230000002068 genetic effect Effects 0.000 description 1
- 229940029575 guanosine Drugs 0.000 description 1
- 238000010438 heat treatment Methods 0.000 description 1
- 230000009610 hypersensitivity Effects 0.000 description 1
- 230000028993 immune response Effects 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- 230000010354 integration Effects 0.000 description 1
- 230000009545 invasion Effects 0.000 description 1
- 238000002955 isolation Methods 0.000 description 1
- 150000002617 leukotrienes Chemical class 0.000 description 1
- 238000012417 linear regression Methods 0.000 description 1
- 230000033001 locomotion Effects 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 201000005202 lung cancer Diseases 0.000 description 1
- 201000005296 lung carcinoma Diseases 0.000 description 1
- 208000020816 lung neoplasm Diseases 0.000 description 1
- 230000001404 mediated effect Effects 0.000 description 1
- 210000001616 monocyte Anatomy 0.000 description 1
- 210000003097 mucus Anatomy 0.000 description 1
- 230000003448 neutrophilic effect Effects 0.000 description 1
- 230000009871 nonspecific binding Effects 0.000 description 1
- 231100000252 nontoxic Toxicity 0.000 description 1
- 230000003000 nontoxic effect Effects 0.000 description 1
- 239000002674 ointment Substances 0.000 description 1
- 230000002018 overexpression Effects 0.000 description 1
- 230000035515 penetration Effects 0.000 description 1
- 229940049954 penicillin Drugs 0.000 description 1
- 230000000737 periodic effect Effects 0.000 description 1
- 230000002688 persistence Effects 0.000 description 1
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 1
- 239000010452 phosphate Substances 0.000 description 1
- 239000002953 phosphate buffered saline Substances 0.000 description 1
- 150000008300 phosphoramidites Chemical class 0.000 description 1
- 230000001766 physiological effect Effects 0.000 description 1
- 239000013612 plasmid Substances 0.000 description 1
- 231100000374 pneumotoxicity Toxicity 0.000 description 1
- 229920000573 polyethylene Polymers 0.000 description 1
- 239000003380 propellant Substances 0.000 description 1
- 229940043274 prophylactic drug Drugs 0.000 description 1
- 230000000069 prophylactic effect Effects 0.000 description 1
- 230000007047 pulmonary toxicity Effects 0.000 description 1
- 230000029058 respiratory gaseous exchange Effects 0.000 description 1
- 108091008146 restriction endonucleases Proteins 0.000 description 1
- 238000003757 reverse transcription PCR Methods 0.000 description 1
- 238000012552 review Methods 0.000 description 1
- 206010039083 rhinitis Diseases 0.000 description 1
- 230000007017 scission Effects 0.000 description 1
- 239000002904 solvent Substances 0.000 description 1
- 241000894007 species Species 0.000 description 1
- 230000002269 spontaneous effect Effects 0.000 description 1
- 238000012453 sprague-dawley rat model Methods 0.000 description 1
- 230000000638 stimulation Effects 0.000 description 1
- 229960005322 streptomycin Drugs 0.000 description 1
- 238000010254 subcutaneous injection Methods 0.000 description 1
- 239000007929 subcutaneous injection Substances 0.000 description 1
- 150000008163 sugars Chemical class 0.000 description 1
- 239000000375 suspending agent Substances 0.000 description 1
- 229940126585 therapeutic drug Drugs 0.000 description 1
- 230000000699 topical effect Effects 0.000 description 1
- 230000001960 triggered effect Effects 0.000 description 1
- 241000712461 unidentified influenza virus Species 0.000 description 1
- 230000003612 virological effect Effects 0.000 description 1
- 238000005303 weighing Methods 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
- A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
- A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
- A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
- A61K31/7076—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines containing purines, e.g. adenosine, adenylic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/02—Nasal agents, e.g. decongestants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
- C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
- C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
- C07H19/16—Purine radicals
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
- C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
- C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
- C07H19/23—Heterocyclic radicals containing two or more heterocyclic rings condensed among themselves or condensed with a common carbocyclic ring system, not provided for in groups C07H19/14 - C07H19/22
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H21/00—Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H21/00—Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids
- C07H21/04—Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids with deoxyribosyl as saccharide radical
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
- C12N15/1138—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against receptors or cell surface proteins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/31—Chemical structure of the backbone
- C12N2310/315—Phosphorothioates
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/33—Chemical structure of the base
- C12N2310/333—Modified A
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Genetics & Genomics (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Molecular Biology (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Biochemistry (AREA)
- Biotechnology (AREA)
- Biomedical Technology (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- General Engineering & Computer Science (AREA)
- Immunology (AREA)
- Physics & Mathematics (AREA)
- Biophysics (AREA)
- Microbiology (AREA)
- Plant Pathology (AREA)
- Pulmonology (AREA)
- Oncology (AREA)
- Virology (AREA)
- Communicable Diseases (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Epidemiology (AREA)
- Hospice & Palliative Care (AREA)
- Cardiology (AREA)
- Pain & Pain Management (AREA)
- Otolaryngology (AREA)
- Ophthalmology & Optometry (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US30307101P | 2001-07-06 | 2001-07-06 | |
| US303071P | 2001-07-06 | ||
| PCT/CA2002/001046 WO2003004511A2 (en) | 2001-07-06 | 2002-07-08 | Methods for increasing in vivo efficacy of oligonucleotides and inhibiting inflammation in mammals |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| DE60225141D1 DE60225141D1 (de) | 2008-04-03 |
| DE60225141T2 true DE60225141T2 (de) | 2009-03-05 |
Family
ID=23170407
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| DE60225141T Expired - Lifetime DE60225141T2 (de) | 2001-07-06 | 2002-07-08 | Verfahren zur erhöhung der in vivo wirksamkeit von oligonukleotiden und zur entzündungshemmung in säugetieren |
Country Status (13)
| Country | Link |
|---|---|
| US (2) | US7745420B2 (enExample) |
| EP (1) | EP1406667B1 (enExample) |
| JP (1) | JP4903984B2 (enExample) |
| AT (1) | ATE386548T1 (enExample) |
| AU (1) | AU2002319033B2 (enExample) |
| CA (1) | CA2451738C (enExample) |
| DE (1) | DE60225141T2 (enExample) |
| DK (1) | DK1406667T3 (enExample) |
| ES (1) | ES2301659T3 (enExample) |
| MX (1) | MXPA04000162A (enExample) |
| NZ (1) | NZ530360A (enExample) |
| PT (1) | PT1406667E (enExample) |
| WO (1) | WO2003004511A2 (enExample) |
Families Citing this family (16)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2006045202A1 (en) * | 2004-10-29 | 2006-05-04 | Topigen Pharmaceuticals Inc. | Antisense oligonucleotides for treating allergy and neoplastic cell proliferation |
| ES2373246T3 (es) | 2006-08-11 | 2012-02-01 | Prosensa Technologies B.V. | Oligonucleótidos monocatenarios complementarios de elementos repetitivos para el tratamiento de trastornos genéticos asociados a la inestabilidad de repeticiones de adn. |
| USRE48468E1 (en) | 2007-10-26 | 2021-03-16 | Biomarin Technologies B.V. | Means and methods for counteracting muscle disorders |
| HUE028662T2 (en) | 2007-10-26 | 2016-12-28 | Academisch Ziekenhuis Leiden | Preparations and methods for controlling muscle disorders |
| EP2119783A1 (en) | 2008-05-14 | 2009-11-18 | Prosensa Technologies B.V. | Method for efficient exon (44) skipping in Duchenne Muscular Dystrophy and associated means |
| EP2285961A4 (en) * | 2008-05-15 | 2012-10-17 | Topigen Pharmaceuticals Inc | OLIGONUCLEOTIDES FOR THE TREATMENT OF INFLAMMATION AND NEOPLASTIC CELL REPRODUCTION |
| WO2010048731A1 (en) * | 2008-10-31 | 2010-05-06 | Christopher John Ong | Aminoacyl trna-synthetase inhibitors as broad-spectrum immunosuppressive agents |
| US9622909B2 (en) | 2009-02-26 | 2017-04-18 | Advanced Cooling Therapy, Inc. | Devices and methods for controlling patient temperature |
| MY183870A (en) * | 2009-02-26 | 2021-03-17 | Advanced Cooling Therapy Llc | Devices and methods for controlling patient temperature |
| US9301871B2 (en) | 2009-02-26 | 2016-04-05 | Advanced Cooling Therapy, Inc. | Devices and methods for controlling patient temperature |
| US9326890B2 (en) | 2009-02-26 | 2016-05-03 | Advanced Cooling Therapy, Inc. | Devices and methods for controlling patient temperature |
| SG192869A1 (en) * | 2011-02-24 | 2013-09-30 | Pharmaxis Ltd | Oligonucleotide inhibitors with chimeric backbone and 2-amino-2'-deoxyadenosine |
| CN111893117B (zh) | 2012-01-27 | 2024-06-04 | 比奥马林技术公司 | 治疗杜兴型肌营养不良症和贝克型肌营养不良症的具有改善特性的rna调节性寡核苷酸 |
| US9272016B2 (en) * | 2012-04-20 | 2016-03-01 | University Of Iowa Research Foundation | Methods to enhance RNAi oligonucleotide delivery to respiratory epithelial cells |
| HRP20171254T1 (hr) * | 2012-04-23 | 2018-01-12 | Biomarin Technologies B.V. | Oligonukleotidi koji moduliraju rnk s poboljšanim karakteristikama za liječenje neuromišićnih poremećaja |
| FR3057774B1 (fr) * | 2016-10-21 | 2025-11-07 | Museum Nat Dhistoire Naturelle | Derives de la purine pour leur utilisation dans le traitement ou la prevention de maladies dues a une mutation non-sens |
Family Cites Families (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3337530A (en) | 1965-09-20 | 1967-08-22 | Upjohn Co | Dinucleoside 3', 5' -and 2', 5'-phosphates containing one 7-deazapurin riboside moiety |
| JPH01173818A (ja) * | 1987-12-28 | 1989-07-10 | Aisin Aw Co Ltd | 車両用ナビゲーション装置 |
| US5523205A (en) * | 1988-08-02 | 1996-06-04 | Institut Pasteur | DNA probes specific for hemolytic listeria |
| US5646265A (en) * | 1990-01-11 | 1997-07-08 | Isis Pharmceuticals, Inc. | Process for the preparation of 2'-O-alkyl purine phosphoramidites |
| US5112961A (en) * | 1990-07-18 | 1992-05-12 | Schering Corporation | Dna encoding subunits of a high affinity gm-csf receptor |
| EP0509826A1 (en) * | 1991-04-19 | 1992-10-21 | Schering Corporation | Subunit of the human interleukin 3 receptor |
| US5872242A (en) | 1992-10-05 | 1999-02-16 | Isis Pharmaceuticals, Inc. | Antisense oligonucleotide inhibition of ras |
| GB9301000D0 (en) * | 1993-01-20 | 1993-03-10 | Glaxo Group Ltd | Chemical compounds |
| US6077668A (en) * | 1993-04-15 | 2000-06-20 | University Of Rochester | Highly sensitive multimeric nucleic acid probes |
| CA2235420A1 (en) * | 1998-06-17 | 1999-12-17 | Paolo Renzi | Antisense oligonucleotides for treating or preventing atopic diseases and neoplastic cell proliferation |
| EP1088066B1 (en) * | 1998-06-19 | 2006-11-29 | McGILL UNIVERSITY | Antisense oligonucleotide constructs based on beta-arabinofuranose and its analogues |
| CA2333901A1 (en) * | 1998-08-03 | 2000-02-24 | East Carolina University | Low adenosine anti-sense oligonucleotide agent, composition, kit and treatments |
| US6175004B1 (en) * | 1998-09-01 | 2001-01-16 | Isis Pharmaceuticals, Inc. | Process for the synthesis of oligonucleotides incorporating 2-aminoadenosine |
| IL140054A0 (en) | 1999-04-06 | 2002-02-10 | Univ East Carolina | Low adenosine anti-sense oligonucleotide, compositions, kit and method for treatment of airway disorders associated with bronchoconstriction, lung inflammation, allergy (ies) and surfactant depletion |
-
2002
- 2002-07-08 DK DK02748499T patent/DK1406667T3/da active
- 2002-07-08 PT PT02748499T patent/PT1406667E/pt unknown
- 2002-07-08 EP EP02748499A patent/EP1406667B1/en not_active Expired - Lifetime
- 2002-07-08 JP JP2003510677A patent/JP4903984B2/ja not_active Expired - Fee Related
- 2002-07-08 NZ NZ530360A patent/NZ530360A/en not_active IP Right Cessation
- 2002-07-08 US US10/482,949 patent/US7745420B2/en not_active Expired - Fee Related
- 2002-07-08 AT AT02748499T patent/ATE386548T1/de active
- 2002-07-08 AU AU2002319033A patent/AU2002319033B2/en not_active Ceased
- 2002-07-08 ES ES02748499T patent/ES2301659T3/es not_active Expired - Lifetime
- 2002-07-08 CA CA2451738A patent/CA2451738C/en not_active Expired - Fee Related
- 2002-07-08 WO PCT/CA2002/001046 patent/WO2003004511A2/en not_active Ceased
- 2002-07-08 DE DE60225141T patent/DE60225141T2/de not_active Expired - Lifetime
- 2002-07-08 MX MXPA04000162A patent/MXPA04000162A/es active IP Right Grant
-
2009
- 2009-05-06 US US12/436,493 patent/US20100286235A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| US7745420B2 (en) | 2010-06-29 |
| CA2451738A1 (en) | 2003-01-16 |
| MXPA04000162A (es) | 2006-05-22 |
| DE60225141D1 (de) | 2008-04-03 |
| ATE386548T1 (de) | 2008-03-15 |
| JP2004532900A (ja) | 2004-10-28 |
| ES2301659T3 (es) | 2008-07-01 |
| US20100286235A1 (en) | 2010-11-11 |
| CA2451738C (en) | 2013-09-17 |
| US20050032723A1 (en) | 2005-02-10 |
| AU2002319033B2 (en) | 2008-01-10 |
| JP4903984B2 (ja) | 2012-03-28 |
| DK1406667T3 (da) | 2008-06-16 |
| EP1406667A2 (en) | 2004-04-14 |
| WO2003004511A2 (en) | 2003-01-16 |
| EP1406667B1 (en) | 2008-02-20 |
| WO2003004511A3 (en) | 2003-07-10 |
| PT1406667E (pt) | 2008-05-23 |
| NZ530360A (en) | 2006-01-27 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| DE60225141T2 (de) | Verfahren zur erhöhung der in vivo wirksamkeit von oligonukleotiden und zur entzündungshemmung in säugetieren | |
| DE69413529T2 (de) | Antivirale verbindungen | |
| DE60131430T2 (de) | Oligodeoxynukleotide und ihre verwendung zur induktion einer immunreaktion | |
| EP1409670B1 (de) | Synthetische doppelsträngige oligonucleotide zur gezielten hemmung der genexpression | |
| DE60131250T2 (de) | Nucleosid-analoga mit monozyklischen basischen carboxamidingruppen | |
| DE69716255T2 (de) | Verfahren zur behandlung von mittelohrentzündung mittels uridintriphosphaten und verwandten mitteln | |
| DE69415343T2 (de) | 2'-amido-und 2'-peptido-modifizierte oligonukleotide | |
| DE69219482T2 (de) | Mit einer einfach ungesättigten omega-9 C18 or C20 Fettsäure O-acylierte Nukleoside | |
| EP0653439A2 (de) | Stabilisierte Oligonucleotide und deren Verwendung | |
| WO1997035591B1 (en) | Method of treating ciliary dyskinesia with uridine triphosphates and related compounds | |
| DE69724991T2 (de) | Behandlung von bronchitis mit diuridintretraphosphat | |
| DE69928932T2 (de) | Antisense oligonukleotide zur behandlung von atopischen krankheiten und neoplastischer zellvermehrung | |
| EP1348466A2 (en) | Method for treating pain with adenosine-tetraphosphates | |
| AU2002319033A1 (en) | Methods for increasing in vivo efficacy of oligonucleotides and inhibiting inflammation in mammals | |
| EP0409227A2 (de) | Pyrimidinnucleoside, ihre Herstellung und pharmazeutische Mittel | |
| EP1204430B1 (de) | Konjugate und verfahren zu deren herstellung sowie deren verwendung zum transport von molekülen über biologische membranen | |
| JP2004532900A5 (enExample) | ||
| DE4331670A1 (de) | Neue Antisense-Oligonucleotide gegen HSV-1 sowie deren Herstellung | |
| DE3873207T2 (de) | Antivirale therapie gegen hepatitis b mit 2',3'-didesoxynucleosiden. | |
| EP2289520A1 (de) | Verwendung von Acetylsalicylsäure zur Prophylaxe und/oder Therapie von Influenzavirus Infekten. | |
| DE3734962C1 (de) | Verwendung von Chondroitinpolysulfat zur vorbeugenden,lindernden oder heilenden Behandlung von AIDS und ARC | |
| DE60210070T2 (de) | Sulfatierte polysaccharide und verfahren zur behandlung von entzündungen unter verwendung derselben | |
| EP1414961B1 (de) | Neue oligoribonucleotid-derivate zur gezielten hemmung der genexpression | |
| DE60132581T2 (de) | Medikament zur behandlung von durch parasitäre protozoen verursachte erkrankungen | |
| EP1692284B1 (de) | Anti-apoptotisch wirksame apatamere |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| 8381 | Inventor (new situation) |
Inventor name: RENZI, PAOLO, WESTMOUNT, QUEBEC, CA Inventor name: ALLAM, MUSTAPHA, MONTREAL, QUEBEC, CA Inventor name: ALLAKHVERDI, ZOULFIA, MONTREAL, QUEBEC, CA |
|
| 8364 | No opposition during term of opposition |